Genmab

Genmab A/S is a Danish biotechnology company that discovers and develops antibody therapeutics for cancer and other diseases. Headquartered in Copenhagen, it operates globally through collaborative agreements with pharmaceutical companies and its own development programs. The company focuses on creating monoclonal and bispecific antibodies using in-house and partnered platforms, with the aim of improving target specificity and immune system engagement.

Genmab employs proprietary antibody engineering platforms, notably DuoBody, a technology to create bispecific antibodies by combining two monoclonal antibodies into one molecule, and HexaBody, which is designed to enhance immune cell recruitment and tumor cell killing. These platforms support a pipeline of partnered and internal candidates across hematologic and solid tumors.

One of Genmab's most notable relationships is with Janssen Biotech (a Johnson & Johnson company) for the development and commercialization of daratumumab (Darzalex), a CD38-targeting monoclonal antibody approved for multiple myeloma and other indications. Genmab typically collaborates with Janssen under licensing and co-development terms and may receive milestone payments and royalties.

Genmab has additional collaborations with other industry partners to advance additional antibody therapeutics and bispecifics in its pipeline. The company has research facilities in Denmark and the United States, with a global organization supporting discovery, development, and early manufacturing activities.

Genmab is publicly traded and has a global investor base, with reporting obligations in Denmark and abroad. The company emphasizes sustainable growth through science-led development and strategic partnerships.